VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO Italy 2022 | The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myeloma

Hans Lee, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the important role of BCMA-targeting antibody drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs) in relapsed/refractory (R/R) multiple myeloma. Dr Lee first discusses the use of belantamab mafodotin, and then goes on to discuss various BiTEs in clinical development, including teclistamab, elranatamab, and alnuctamab. To conclude, Dr Lee highlights the importance of monitoring infection risk when treating patients with these agents. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter